Acalatinib/Acalabrutinib: treatment cycle of a box of drugs

Acalabrutinib, a highly potent kinase inhibitor, provides a new treatment option for adult patients, especially those with mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL) who have undergone one or more treatments.

Its unique therapeutic mechanism lies in forming a stable covalent bond with the cysteine residue in the active site of BTK, thus effectively inhibiting the activity of BTK enzyme. BTK, as a core molecule in the B cell antigen receptor (BCR) and cytokine receptor signaling pathways, plays a regulatory role in multiple biological processes of B cells. By blocking BTK, acotinib cuts off the signaling network that supports the survival and reproduction of malignant B cells.

Patients should follow medical advice when using acotinib. The usually recommended dose is 100 mg orally every 12 hours. It is easy to take. Just swallow the capsule whole with water. It is not recommended to split or chew it. If you miss an occasional dose, you should not compensate by doubling the dose.

Common acotinib packaging specifications on the market include 100mg*8 tablets, 7 plates or 100mg*60 tablets. Based on these specifications, patients taking one box of acotinib can roughly maintain treatment for one month. However, it is worth noting that the actual medication cycle for each patient may vary depending on the condition, physical differences, and the doctor's personalized recommendations.

In general, acotinib, as a kinase inhibitor, plays an important role in treating diseases. By inhibiting BTK enzyme activity, it blocks the proliferation and survival of malignant B cells, providing patients with new treatment options. During the taking process, patients need to follow the doctor's advice, take it on time and in the right amount, and pay attention to possible side effects and toxic reactions.